Stock listing

Xetra:1RV Rhythm Pharmaceuticals, Inc. Aktie

German listing (Xetra) of Rhythm Pharmaceuticals, Inc. · home listing NASDAQ:RYTM

Follow Rhythm Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:RYTM

$112.36 USD -6.68 (-5.6%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:RYTM

Past year +11.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$112.00 – $117.01 USDNov 20, 2026
Volume
1.50M sharesNov 20, 2026
Market cap
$7.79B USDAt the close on Nov 20, 2026 · price × 69.33M shares outstanding
52-week range
$74.50 – $122.20 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$109.2M USDMedian day 644,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Rhythm Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:RYTM · Home$112.36 USD-6.68 (-5.6%)1,502,362$115.46$117.01$112.00$119.04Close on Nov 20, 2026
Frankfurt:1RV€100.00 EUR-2.00 (-2.0%)—€105.00€105.00€100.00€102.00Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RYTM · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$112.36-6.68-5.6%$115.46$117.01$112.001,502,362
$119.04+2.43+2.1%$115.72$121.41$114.592,014,530
$116.61+9.13+8.5%$106.81$118.50$104.202,563,407
$107.48-7.54-6.6%$113.23$114.93$107.21947,267
$115.02+5.16+4.7%$109.81$117.84$107.861,144,113
$109.86-2.30-2.1%$112.26$112.26$108.941,054,918
$112.16-1.79-1.6%$113.76$115.20$112.04734,161
$113.95+0.010.0%$113.42$115.06$112.51616,028
$113.94+1.66+1.5%$112.30$114.98$110.781,286,798
$112.28+7.26+6.9%$107.10$113.29$104.314,928,737
$105.02-5.66-5.1%$108.76$110.66$103.066,396,436
$110.68+24.24+28.0%$85.94$110.68$85.045,489,582
$86.44-7.00-7.5%$84.83$89.28$81.587,110,007
$93.44+0.87+0.9%$93.13$95.35$92.402,003,953
$92.57-0.50-0.5%$93.48$95.60$91.42431,700
$93.07+1.10+1.2%$93.00$94.16$92.52760,500
$91.97-0.21-0.2%$91.37$92.70$91.05533,900
$92.18+2.71+3.0%$89.36$92.72$88.72400,200
$89.47+0.20+0.2%$90.07$90.81$89.00289,400
$89.27-1.63-1.8%$90.44$90.44$88.56536,900
$90.90+2.28+2.6%$88.85$90.95$87.59516,400
$88.62-1.58-1.8%$91.02$92.18$88.12511,300
$90.20+1.97+2.2%$88.56$91.88$88.56877,000
$88.23+2.06+2.4%$87.04$88.76$86.59378,800
$86.17-1.80-2.0%$88.20$88.62$85.91367,000
$87.97+1.26+1.5%$88.41$90.42$87.61644,600
$86.71+0.10+0.1%$86.41$88.14$85.38585,800
$86.61-3.21-3.6%$89.63$90.51$86.35623,000
$89.82-0.96-1.1%$91.05$91.42$89.49543,800
$90.78+1.14+1.3%$89.67$93.35$89.411,411,400
$89.64+1.19+1.3%$89.05$90.94$87.011,008,500
$88.45-2.32-2.6%$90.77$91.37$88.23939,400
$90.77-1.68-1.8%$92.55$94.47$90.07992,900
$92.45-0.38-0.4%$93.95$94.41$89.531,027,200
$92.83-0.58-0.6%$94.97$95.32$92.66503,500
$93.41-1.805-1.9%$95.34$96.48$93.00850,600
$95.22-0.495-0.5%$96.67$97.37$95.10737,200
$95.71-2.85-2.9%$97.92$98.91$94.51810,900
$98.56-0.10-0.1%$98.01$99.15$95.27897,400
$98.66+0.35+0.4%$98.41$99.45$96.35864,300
$98.31+0.07+0.1%$97.73$99.28$95.38730,800
$98.24-1.03-1.0%$99.27$100.02$96.47696,400
$99.27+0.44+0.4%$100.44$101.85$98.69499,900
$98.83+1.12+1.1%$98.47$100.76$97.54613,600
$97.71-1.31-1.3%$99.36$99.36$96.881,124,800
$99.02+1.01+1.0%$101.17$102.00$98.80617,700
$98.01+1.24+1.3%$97.69$100.85$97.06921,400
$96.77-5.67-5.5%$101.66$101.66$96.14914,300
$102.44-2.27-2.2%$105.27$105.93$101.09789,700
$104.71+2.51+2.5%$102.96$106.57$102.25573,700
$102.20+1.14+1.1%$99.88$102.89$99.88422,900
$101.06-0.74-0.7%$100.23$101.77$99.83478,600
$101.80-0.94-0.9%$100.58$103.31$99.41513,000
$102.74-2.15-2.0%$103.53$105.71$101.25466,900
$104.89-0.53-0.5%$106.08$106.08$103.90269,800
$105.42+0.68+0.6%$105.50$108.57$103.95455,600
$104.74-1.39-1.3%$105.79$108.43$104.09332,000
$106.13-1.04-1.0%$106.01$108.85$103.98775,200
$107.17-5.36-4.8%$110.21$114.75$107.09441,200
$112.53+0.66+0.6%$111.21$113.97$110.03311,100
$111.87-1.48-1.3%$113.21$114.75$111.35359,000
$113.35+1.91+1.7%$112.73$114.07$111.79352,500
$111.44+1.44+1.3%$112.29$113.60$109.89400,600
$110.00+1.08+1.0%$109.38$112.59$106.58523,100
$108.92-6.81-5.9%$114.51$114.61$108.73568,600
Ticker
Xetra:1RV
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
Xetra
Currency
EUR

What changed lately

Latest news

All Rhythm Pharmaceuticals, Inc. news

Rhythm Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
37 in the last 12 months · 225 in all · newest Nov 16, 2026 · oldest 2019
Calls
22 calls with a replay · 22 with a transcript · latest Nov 3, 2026
Decks
61 decks · latest Nov 3, 2026

Where Rhythm Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:RYTM · Home listingNASDAQUnited StatesUSD
LS Exchange:A2H5A0LS ExchangeGermanyEUR
Lang & Schwarz:A2H5A0Lang & SchwarzGermanyEUR
gettex:1RVgettexGermanyEUR
Tradegate:1RVTradegateGermanyEUR
BMV:RYTMBMVMexicoMXN
BOATS:RYTMBOATSUnited StatesUSD
Frankfurt:1RVFrankfurtGermanyEUR
BIVA:RYTMBIVAMexicoMXN
Dusseldorf:1RVDusseldorfGermanyEUR
Munich:1RVMunichGermanyEUR
Stuttgart:1RVStuttgartGermanyEUR
Xetra:1RV · This pageXetraGermanyEUR

Valuation

EV/sales 27.0× against a median of 4.4×: the highest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$7.57B USD
P/E
Loss
EV/sales
27.0×
EV/EBITDA
Negative EBITDA
Price/book
88.6×
Gross margin
88.2%
Operating margin
−66.7%
Net margin
−69.0%
Debt to equity
1.2×
Beta vs S&P 500
1.20

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Rhythm Pharmaceuticals, Inc. · NASDAQ:RYTMUS$7.79BUS$7.57Bn/a27.0×n/a88.6×−69.0%1.2×1.20
Haisco Pharmaceutical Group Co. Ltd. Class A · SZSE:002653US$8.97BUS$8.66B44.7×9.5×n/a10.1×22.1%0.1×n/a
Madrigal Pharmaceuticals, Inc. · NASDAQ:MDGLUS$8.81BUS$8.19Bn/a5.7×n/a14.1×−10.9%0.5×0.50
Glenmark Pharmaceuticals Limited · NSE:GLENMARKUS$8.06BUS$8.05B51.5×4.7×22.6×6.7×9.2%0.1×n/a
Amneal Pharmaceuticals, Inc. · NASDAQ:AMRXUS$7.36BUS$10.14B55.2×3.2×16.0×13.8×4.2%5.5×0.67
Chemical Works of Gedeon Richter PLC · BET:RICHTERUS$7.13BUS$6.29B10.4×2.3×5.6×1.8×25.0%0.0×n/a
ALK-abello A/S Class B · OMXCOP:ALK_BUS$7.07BUS$6.82B34.3×6.6×20.9×6.6×19.9%0.1×n/a
Corcept Therapeutics Incorporated · NASDAQ:CORTUS$6.88BUS$6.52B42.4×6.8×57.2×8.3×16.8%0.0×1.59
Alkem Laboratories Ltd. · NSE:ALKEMUS$6.69BUS$6.78B30.0×4.0×20.0×4.2×13.2%0.2×n/a
Huadong Medicine Co., Ltd. Class A · SZSE:000963US$6.53BUS$5.95B12.7×0.9×n/a1.7×7.8%0.0×n/a
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Class A · SZSE:000999US$6.48BUS$5.85B13.4×1.3×n/a1.9×10.4%0.1×n/a
Median of the othersUS$7.10BUS$6.80B34.3×4.4×20.5×6.7×11.8%0.1×0.67

Forecasts

12 strong buy · 5 buy · 2 hold · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
140.12 USD · Analysts' mean
EPS, year to Dec 2026
-4.94 · 14 analysts
Revenue, year to Dec 2026
330.6M · 17 analysts

Team and board

Officers

OfficerRole
David MeekerChairman, President, and Chief Executive Officer
Hunter SmithChief Financial Officer and Treasurer
Jim FlahertySenior Vice President and General Counsel
Elisabeth Crönert-BendellSenior Vice President, Head of Strategy
Jennifer LeeExecutive Vice President, Head of North America
Yann MazabraudExecutive Vice President, Head of International
Alastair GarfieldChief Scientific Officer
Alicia FiscusChief Regulatory Officer
Joe ShulmanChief Technical Officer
Manher AJ JoshiChief Medical Officer

Board

DirectorRole
David MeekerChairman, President, and Chief Executive Officer
Christophe R. JeanDirector
David McGirrDirector
Jennifer GoodDirector
Kimberly J. PopovitsDirector
Lynn TetraultDirector
Stuart ArbuckleDirector

Events

Calls

CallWhenStatus
Rhythm Pharmaceuticals (NASDAQ:RYTM) Q3 2026 Earnings CallTue, Nov 03, 2026 · 8:00 AM ETReplay
Rhythm Pharmaceuticals (NASDAQ:RYTM) Q2 2026 Earnings CallTue, Aug 04, 2026 · 8:00 AM ETReplay
Rhythm Pharmaceuticals (NASDAQ:RYTM) Q1 2026 Earnings CallTue, May 05, 2026 · 8:00 AM ETReplay
Rhythm Pharmaceuticals (NASDAQ:RYTM) Q4 2025 Earnings CallThu, Feb 26, 2026 · 8:00 AM ETReplay
Rhythm Pharmaceuticals (NASDAQ:RYTM) Q3 2025 Earnings CallTue, Nov 04, 2025 · 8:00 AM ETReplay
Rhythm Pharmaceuticals (NASDAQ:RYTM) Q2 2025 Earnings CallTue, Aug 05, 2025 · 8:00 AM ETReplay
Rhythm Pharmaceuticals (NASDAQ:RYTM) Q1 2025 Earnings CallWed, May 07, 2025 · 8:00 AM ETReplay
Rhythm Pharmaceuticals (NASDAQ:RYTM) Q4 2024 Earnings CallWed, Feb 26, 2025 · 8:00 AM ETReplay
Rhythm Pharmaceuticals (NASDAQ:RYTM) Q3 2024 Earnings CallTue, Nov 05, 2024 · 5:00 PM ETReplay
Rhythm Pharmaceuticals (NASDAQ:RYTM) Q2 2024 Earnings CallTue, Aug 06, 2024 · 8:00 AM ETReplay
All 22 calls
CallWhenStatus
Rhythm Pharmaceuticals (NASDAQ:RYTM) Q1 2024 Earnings CallTue, May 07, 2024 · 8:00 AM ETReplay
Rhythm Pharmaceuticals (NASDAQ:RYTM) Q4 2023 Earnings CallThu, Feb 22, 2024 · 8:00 AM ETReplay
Rhythm Pharmaceuticals (NASDAQ:RYTM) Q3 2023 Earnings CallWed, Nov 15, 2023 · 8:00 AM ETReplay
Rhythm Pharmaceuticals (NASDAQ:RYTM) Q2 2023 Earnings CallTue, Aug 01, 2023 · 9:00 AM ETReplay
Rhythm Pharmaceuticals (NASDAQ:RYTM) Q1 2023 Earnings CallTue, May 09, 2023 · 4:40 AM ETReplay
Rhythm Pharmaceuticals (NASDAQ:RYTM) Q4 2022 Earnings CallWed, Mar 01, 2023 · 8:00 AM ETReplay
Rhythm Pharmaceuticals (NASDAQ:RYTM) Q3 2022 Earnings CallTue, Nov 08, 2022 · 8:00 AM ETReplay
Rhythm Pharmaceuticals (NASDAQ:RYTM) Q2 2022 Earnings CallTue, Aug 02, 2022 · 8:00 AM ETReplay
Rhythm Pharmaceuticals (NASDAQ:RYTM) Q1 2022 Earnings CallTue, May 03, 2022 · 8:30 AM ETReplay
Rhythm Pharmaceuticals (NASDAQ:RYTM) Q4 2021 Earnings CallTue, Mar 01, 2022 · 8:00 AM ETReplay
Rhythm Pharmaceuticals (NASDAQ:RYTM) Q3 2021 Earnings CallTue, Nov 02, 2021 · 8:00 AM ETReplay
Rhythm Pharmaceuticals (NASDAQ:RYTM) Q2 2021 Earnings CallTue, Aug 03, 2021 · 8:00 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 3, 2026 · Before open−7.5%
Q2 2026Aug 4, 2026 · Before open+2.9%
Q1 2026May 5, 2026 · Before open+7.9%
Q4 2025Feb 26, 2026−6.5%
Q3 2025Nov 4, 2025 · Before open−7.7%
Q2 2025Aug 5, 2025 · Before open−1.9%
Q1 2025May 7, 2025 · Before open+3.1%
Q4 2024Feb 20, 2025 · Before open−0.5%
Q3 2024Nov 5, 2024 · After close+11.4%
Q2 2024Aug 6, 2024 · Before open+0.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 7, 2024 · Before open−10.3%
Q4 2023Feb 22, 2024 · Before open−9.7%
Q3 2023Nov 7, 2023 · Before open−0.5%
Q2 2023Aug 1, 2023 · Before open+27.5%
Q1 2023May 2, 2023 · Before open−7.3%
Q4 2022Mar 1, 2023 · Before open+6.3%
Q3 2022Nov 8, 2022 · Before open+2.5%
Q2 2022Aug 2, 2022 · Before open+13.8%
Q1 2022May 3, 2022 · Before open−2.7%
Q4 2021Mar 1, 2022 · Before open+11.4%

Open Events

Decks

DeckKindSlidesDate
Q3 2026 Earnings PresentationEarnings29 slidesNov 3, 2026
64th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE) 2026Conference16 slidesSeptember 2026
64th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE) 2026Conference13 slidesSeptember 2026
Investor Presentation (September 2026)Investor deck66 slidesSeptember 2026
Q2 2026 Earnings PresentationEarnings31 slidesAug 4, 2026
ENDO 2026Conference26 slidesJun 15, 2026
ENDO 2026Conference26 slidesJun 13, 2026
Investor Presentation (June 2026)Investor deck52 slidesJune 2026
Q1 2026 Earnings PresentationEarnings23 slidesMay 5, 2026
Investor Presentation (April 2026)Investor deck50 slidesApril 2026
Show 50 decks
DeckKindSlidesDate
Corporate Update (March 2026)Corporate update16 slidesMar 19, 2026
Technical Presentation (March 2026)Technical29 slidesMar 16, 2026
Corporate Update (March 2026)Corporate update29 slidesMar 16, 2026
Q4 2025 Earnings PresentationEarnings28 slidesFeb 26, 2026
Investor Presentation (January 2026)Investor deck61 slidesJan 9, 2026
Technical Presentation (December 2025)Technical21 slidesDec 11, 2025
Corporate Update (November 2025)Corporate update6 slidesNov 7, 2025
Q3 2025 Earnings PresentationEarnings23 slidesNov 4, 2025
Q2 2025 Earnings PresentationEarnings27 slidesAug 5, 2025
Technical Presentation (July 2025)Technical21 slidesJul 9, 2025
Q1 2025 Earnings PresentationEarnings27 slidesMay 7, 2025
32nd European Congress on Obesity 2025Conference15 slidesMay 2025
Conference Presentation (April 2025)Conference27 slidesApr 7, 2025
Q4 2024 Earnings PresentationEarnings21 slidesFeb 26, 2025
Investor Presentation (January 2025)Investor deck48 slidesJan 10, 2025
Q3 2024 Earnings PresentationEarnings25 slidesNov 5, 2024
Q2 2024 Earnings PresentationEarnings23 slidesAug 6, 2024
ENDO 2024Conference5 slidesJune 2024
Q1 2024 Earnings PresentationEarnings20 slidesMay 7, 2024
Pediatric Endocrine Society Annual Meeting 2024Conference12 slidesMay 2024
Q4 2023 Earnings PresentationEarnings32 slidesFeb 22, 2024
Q3 2023 Earnings PresentationEarnings28 slidesNov 15, 2023
ObesityWeek 2023Conference23 slidesOct 18, 2023
ObesityWeek 2023Conference9 slidesOctober 2023
Q2 2023 Earnings PresentationEarnings29 slidesAug 1, 2023
Q1 2023 Earnings PresentationEarnings29 slidesMay 9, 2023
Q4 2022 Earnings PresentationEarnings29 slidesMar 1, 2023
Investor Presentation (January 2023)Investor deck51 slidesJan 9, 2023
Q3 2022 Earnings PresentationEarnings31 slidesNov 8, 2022
ObesityWeek 2022Conference9 slidesNovember 2022
European Society for Paediatric Endocrinology 2022Conference5 slidesSep 15, 2022
Q2 2022 Earnings PresentationEarnings30 slidesAug 2, 2022
Conference Call: Interim results from Phase 2 trial in Hypothalamic Obesity (July 2022)Conference35 slidesJul 12, 2022
Technical Presentation (June 2022)Technical8 slidesJune 2022
Q1 2022 Earnings PresentationEarnings28 slidesMay 3, 2022
The Pediatric Endocrine Society Annual Meeting 2022Conference10 slidesMay 1, 2022
Investor Presentation (April 2022)Investor deck59 slidesApr 6, 2022
Q4 2021 Earnings PresentationEarnings29 slidesMar 1, 2022
Q3 2021 Earnings PresentationEarnings38 slidesNov 2, 2021
ESPE 2021Conference14 slidesSeptember 2021

This page holds 50 of 61 decks. Open Decks

Open Decks

Financings

RaiseDate
Public offering of common stock
Made bigger: about US$175M · US$85 a share · Morgan Stanley +5
Dealers: Morgan Stanley (co-lead), BofA Securities (co-lead), Stifel (co-lead), Wells Fargo Securities (co-lead), Canaccord Genuity, Citizens Capital Markets
Jul 10, 2025
At-the-market programme of common stock
Closed: US$75M raised · US$56.3 a share
Feb 26, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$17.00 a share on Oct 4, 2017.

Price
US$17.00 a share
Shares offered
7,050,000 shares of common stock
Offering size
US$119.8 million
Underwriters' option
Up to 1,057,500 more shares
Listing
RYTM on the Nasdaq Global Market
Underwriters
MORGAN STANLEY, BofA MERRILL LYNCH, COWEN, NEEDHAM & COMPANY · In the order on the cover
Shares delivered
On or about Oct 10, 2017

Steps

StepWhen
Draft sent to the SEC in confidenceOct 13, 2015
Filed publiclySep 5, 2017
Amended onceSep 25, 2017
Shares registered with an exchangeSep 29, 2017
Declared effective by the SECOct 4, 2017
Final prospectus, with the priceOct 5, 2017

Open IPO · From the cover of the final prospectus (424B4) filed Oct 5, 2017

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue189.8M130.1M77.4M23.6M3.15M00000
Cost of revenue19.5M13.4M9.30M2.13M599.0K690.0K834.0K442.0K223.0K144.0K
Gross profit170.3M116.8M68.1M21.5M2.56M-690.0K-834.0K-442.0K-223.0K-144.0K
Research and development167.3M238.0M135.0M108.6M104.1M90.5M109.5M50.3M22.9M19.6M
Selling, general and administrative194.9M144.3M117.5M92.0M68.5M46.1M36.5M28.1M9.52M6.31M
Operating income-192.0M-265.5M-184.4M-179.2M-170.1M-136.6M-146.0M-78.4M-32.4M-25.9M
Depreciation and amortization500.0K700.0K900.0K896.0K816.0K690.0K834.0K442.0K223.0K144.0K
EBITDA-191.5M-264.8M-183.5M-178.3M-169.2M-135.9M-145.2M-78.0M-32.2M-25.8M
Interest expense20.6M20.6M13.9M5.20M100.4M00000
Income before tax-196.0M-260.3M-184.1M-181.1M-69.6M-134.0M-140.7M-74.1M-33.7M-25.9M
Income tax497.0K346.0K564.0K1.96M-1.60M-3.27M-6.11M4.35M1.07M0
Net income-196.5M-260.6M-184.7M-181.1M-69.6M-134.0M-140.7M-74.1M-33.7M-29.1M
Earnings per share, basic-3.11-4.34-3.20-3.47-1.40-3.04-3.86-2.39-2.83-2.85
Earnings per share, diluted-3.11-4.34-3.20-3.47-1.40-3.04-3.86-2.39-2.83-2.85

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents54.3M89.1M60.1M127.7M59.2M100.9M62.3M49.5M34.2M6.54M
Short-term investments334.6M231.4M215.8M205.6M235.6M71.9M230.2M202.5M113.8M4.00M
Receivables26.1M18.5M14.9M6.22M1.02M0
Inventory25.8M18.7M8.62M2.92M111.0K0
Current assets466.9M374.2M308.3M354.2M308.4M181.7M302.4M258.7M150.7M11.2M
Property, plant and equipment1.10M632.0K1.34M2.20M2.81M3.19M3.67M1.12M840.0K930.0K
Goodwill0
Total assets480.2M392.3M332.7M382.5M329.5M187.1M308.5M260.2M151.7M12.3M
Accounts payable13.9M12.3M4.88M4.80M5.74M4.90M10.4M7.64M2.43M1.90M
Current liabilities105.9M115.5M55.2M39.8M43.4M18.0M24.4M13.6M6.72M4.73M
Long-term debt100.9M108.3M106.1M1.34M0
Total debt108.2M109.8M106.1M2.02M2.55M3.09M3.56M
Total liabilities210.2M227.7M163.0M118.2M45.4M20.5M27.5M14.0M6.95M5.04M
Shareholders' equity139.1M21.7M169.8M264.3M284.2M166.5M281.0M246.3M144.8M-32.7M
Shares outstanding67.2M62.4M59.4M56.6M50.3M44.2M44.0M34.4M27.3M10.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-115.7M-113.9M-136.2M-173.4M-146.0M-122.0M-122.8M-62.1M-29.5M-23.2M
Capital spending-953.0K0-47.0K-281.0K-434.0K-214.0K-3.38M-722.0K-133.0K-1.06M
Free cash flow-116.6M-113.9M-136.2M-173.7M-146.4M-122.2M-126.1M-62.8M-29.6M-24.3M
Cash from investing-137.2M-48.2M-5.67M28.0M-62.2M158.5M-28.0M-87.1M-110.0M-5.11M
Cash from financing218.0M191.2M74.4M213.8M166.5M2.01M163.5M164.7M167.2M0
Dividends paid-5.38M-3.97M0
Share buybacks141.5M166.5M2.01M163.5M164.7M167.2M126.4M
Change in cash-34.8M29.2M-67.6M68.4M-41.7M38.6M12.8M15.5M27.7M-28.3M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 20, 2026Insider tradeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
144 · Notice of proposed saleNov 18, 2026Other filingsSEC
144 · Notice of proposed saleNov 17, 2026Other filingsSEC
10-Q · Quarterly reportNov 3, 2026Quarterly reportSEC
8-K · Current reportNov 3, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 13, 2026Big-stake noticeSEC
4 · Change in ownershipSep 14, 2026Insider tradeSEC
144 · Notice of proposed saleSep 14, 2026Other filingsSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
144 · Notice of proposed saleAug 31, 2026Other filingsSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 18, 2026Insider tradeSEC
4 · Change in ownershipAug 17, 2026Insider tradeSEC
4 · Change in ownershipAug 17, 2026Insider tradeSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
144 · Notice of proposed saleAug 13, 2026Other filingsSEC
144 · Notice of proposed saleAug 13, 2026Other filingsSEC
144 · Notice of proposed saleAug 13, 2026Other filingsSEC
144 · Notice of proposed saleAug 12, 2026Other filingsSEC
144 · Notice of proposed saleAug 11, 2026Other filingsSEC
144 · Notice of proposed saleAug 10, 2026Other filingsSEC
10-Q · Quarterly reportAug 4, 2026Quarterly reportSEC
8-K · Current reportAug 4, 2026ResultsSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
8-K · Current reportJun 25, 2026Meeting outcomeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
144 · Notice of proposed saleJun 22, 2026Other filingsSEC
8-K · Current reportJun 15, 2026Current reportSEC
DEFA14A · Additional proxy materialMay 29, 2026Meeting noticeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansMay 5, 2026Offer documentSEC
DEFA14A · Additional proxy materialMay 5, 2026Meeting noticeSEC
10-Q · Quarterly reportMay 5, 2026Quarterly reportSEC
8-K · Current reportMay 5, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeApr 30, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersApr 29, 2026Annual reportSEC
DEF 14A · Proxy statementApr 29, 2026Meeting noticeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 3, 2026Insider tradeSEC
8-K · Current reportApr 3, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 27, 2026Big-stake noticeSEC
8-K · Current reportMar 26, 2026Current reportSEC
8-K · Current reportMar 20, 2026Current reportSEC
8-K · Current reportMar 16, 2026Current reportSEC
4 · Change in ownershipMar 16, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
144 · Notice of proposed saleMar 4, 2026Other filingsSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
144 · Notice of proposed saleMar 3, 2026Other filingsSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
8-K · Current reportMar 2, 2026Current reportSEC
S-3ASR · Registration statementFeb 26, 2026Offer documentSEC
S-8 · Registration statement for employee plansFeb 26, 2026Offer documentSEC
10-K · Annual reportFeb 26, 2026Annual reportSEC
8-K · Current reportFeb 26, 2026ResultsSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 5, 2026Other filingsSEC
144 · Notice of proposed saleFeb 4, 2026Other filingsSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 30, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansJan 16, 2026Offer documentSEC
8-K · Current reportJan 9, 2026ResultsSEC
8-K · Current reportDec 19, 2025Management or board changeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
144 · Notice of proposed saleDec 11, 2025Other filingsSEC
8-K · Current reportDec 11, 2025Current reportSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
144 · Notice of proposed saleNov 20, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
144 · Notice of proposed saleNov 10, 2025Other filingsSEC
144 · Notice of proposed saleNov 7, 2025Other filingsSEC
8-K · Current reportNov 7, 2025Current reportSEC
10-Q · Quarterly reportNov 4, 2025Quarterly reportSEC
8-K · Current reportNov 4, 2025ResultsSEC
4 · Change in ownershipNov 3, 2025Insider tradeSEC
4 · Change in ownershipOct 30, 2025Insider tradeSEC
144 · Notice of proposed saleOct 30, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 30, 2025Big-stake noticeSEC
144 · Notice of proposed saleOct 28, 2025Other filingsSEC
4 · Change in ownershipOct 20, 2025Insider tradeSEC
144 · Notice of proposed saleOct 16, 2025Other filingsSEC
4 · Change in ownershipSep 4, 2025Insider tradeSEC
144 · Notice of proposed saleSep 2, 2025Other filingsSEC
4 · Change in ownershipAug 25, 2025Insider tradeSEC
144 · Notice of proposed saleAug 21, 2025Other filingsSEC
4 · Change in ownershipAug 14, 2025Insider tradeSEC
4 · Change in ownershipAug 14, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
4 · Change in ownershipAug 13, 2025Insider tradeSEC
144 · Notice of proposed saleAug 12, 2025Other filingsSEC
144 · Notice of proposed saleAug 12, 2025Other filingsSEC
144 · Notice of proposed saleAug 11, 2025Other filingsSEC
10-Q · Quarterly reportAug 5, 2025Quarterly reportSEC
8-K · Current reportAug 5, 2025ResultsSEC
4 · Change in ownershipJul 29, 2025Insider tradeSEC
4 · Change in ownershipJul 11, 2025Insider tradeSEC
4 · Change in ownershipJul 11, 2025Insider tradeSEC
4 · Change in ownershipJul 11, 2025Insider tradeSEC
4 · Change in ownershipJul 11, 2025Insider tradeSEC
8-K · Current reportJul 11, 2025Current reportSEC
424B5 · ProspectusJul 10, 2025Offer documentSEC
424B5 · ProspectusJul 9, 2025Offer documentSEC
8-K · Current reportJul 9, 2025Current reportSEC
144 · Notice of proposed saleJul 9, 2025Other filingsSEC
144 · Notice of proposed saleJul 9, 2025Other filingsSEC
144 · Notice of proposed saleJul 9, 2025Other filingsSEC
144 · Notice of proposed saleJul 9, 2025Other filingsSEC
4 · Change in ownershipJul 8, 2025Insider tradeSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
8-K · Current reportJun 26, 2025Meeting outcomeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
144 · Notice of proposed saleJun 10, 2025Other filingsSEC
144 · Notice of proposed saleJun 6, 2025Other filingsSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
144 · Notice of proposed saleJun 3, 2025Other filingsSEC
144 · Notice of proposed saleJun 3, 2025Other filingsSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
144 · Notice of proposed saleMay 30, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 13, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 7, 2025Quarterly reportSEC
8-K · Current reportMay 7, 2025ResultsSEC
4 · Change in ownershipMay 1, 2025Insider tradeSEC
4 · Change in ownershipMay 1, 2025Insider tradeSEC
144 · Notice of proposed saleApr 29, 2025Other filingsSEC
144 · Notice of proposed saleApr 29, 2025Other filingsSEC
ARS · Annual report to shareholdersApr 29, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 24, 2025Big-stake noticeSEC
PRE 14A · Preliminary proxy statementApr 18, 2025Meeting noticeSEC
4 · Change in ownershipApr 16, 2025Insider tradeSEC
4 · Change in ownershipApr 10, 2025Insider tradeSEC
4 · Change in ownershipApr 10, 2025Insider tradeSEC
144 · Notice of proposed saleApr 8, 2025Other filingsSEC
144 · Notice of proposed saleApr 8, 2025Other filingsSEC
8-K · Current reportApr 7, 2025Current reportSEC
4 · Change in ownershipMar 24, 2025Insider tradeSEC
8-K · Current reportMar 20, 2025Current reportSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
144 · Notice of proposed saleMar 14, 2025Other filingsSEC
S-8 · Registration statement for employee plansFeb 28, 2025Offer documentSEC
8-K · Current reportFeb 28, 2025Current reportSEC
10-K · Annual reportFeb 28, 2025Annual reportSEC
8-K · Current reportFeb 26, 2025ResultsSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC

This page holds 200 of 841 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Rhythm Pharmaceuticals, Inc.’s releases · as of Nov 2, 2026

Common shares
69,330,906
Fully diluted
69,330,906

Fully diluted

LineSharesAs of
Common shares69,330,906Nov 2, 2026

Share count over time

CountShares
Nov 2, 202669,330,906

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Vanguard6.7MUS$638MSep 30, 2026
Ra Capital Management, L.P.6.67MUS$635MSep 30, 2026
BlackRock5.98MUS$569MSep 30, 2026
Baker Bros. Advisors LP5.6MUS$534MSep 30, 2026
JPMorgan3.56MUS$341MSep 30, 2026
Primecap Management Co3.06MUS$292MSep 30, 2026
State Street2.64MUS$251MSep 30, 2026
Perceptive Advisors LLC2.53MUS$241MSep 30, 2026
Westfield Capital Management Co LP2.48MUS$236MSep 30, 2026
T. Rowe Price2.33MUS$222MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Goldman Sachs2.12MUS$202MSep 30, 2026
Federated Hermes, Inc.1.88MUS$179MSep 30, 2026
Capital Group1.82MUS$173MSep 30, 2026
Polar Capital Holdings Plc1.66MUS$158MSep 30, 2026
Geode Capital1.55MUS$148MSep 30, 2026
Franklin Templeton1.38MUS$140MSep 30, 2026
Checkpoint Capital L.P.1.22MUS$116MSep 30, 2026
Orbis Allan Gray Ltd1.2MUS$114MSep 30, 2026
Siren, L.L.C.1.09MUS$103MSep 30, 2026
Pictet Asset Management Holding SA976KUS$93MSep 30, 2026
Fidelity914KUS$87.1MSep 30, 2026
Morgan Stanley913KUS$86.9MSep 30, 2026
Janus Henderson859KUS$81.8MSep 30, 2026
AllianceBernstein840KUS$79.9MSep 30, 2026
UBS790KUS$75.2MSep 30, 2026
Woodline Partners LP759KUS$72.3MSep 30, 2026
Point72 Asset Management, L.P.726KUS$69.2MSep 30, 2026
Rock Springs Capital Management LP693KUS$65.9MSep 30, 2026
Invesco663KUS$63.2MSep 30, 2026
Wellington609KUS$58MSep 30, 2026
Schwab590KUS$56.2MSep 30, 2026
Northern Trust549KUS$52.3MSep 30, 2026
Sofinnova Investments, Inc.535KUS$50.9MSep 30, 2026
Longaeva Partners L.P.516KUS$49.2MSep 30, 2026
Loomis Sayles & Co L P442KUS$42MSep 30, 2026
Squarepoint Ops LLC441KUS$42MSep 30, 2026
Orbimed Advisors LLC408KUS$38.8MSep 30, 2026
BNY389KUS$37MSep 30, 2026
Artisan Partners Limited Partnership379KUS$36.1MSep 30, 2026
Bank of America364KUS$34.7MSep 30, 2026
Assenagon Asset Management S.A.363KUS$34.6MSep 30, 2026
Candriam S.C.A.352KUS$33.7MSep 30, 2026
Silverarc Capital Management, LLC348KUS$33.2MSep 30, 2026
Citadel317KUS$30.2MSep 30, 2026
Millennium316KUS$30.1MSep 30, 2026
Ameriprise311KUS$29.7MSep 30, 2026
Voya Investment Management LLC276KUS$26.3MSep 30, 2026
Adage Capital Partners Gp, L.L.C.274KUS$26.1MSep 30, 2026
Duquesne Family Office LLC270KUS$25.7MSep 30, 2026
Braidwell LP256KUS$24.4MSep 30, 2026

This page holds 50 of 322 holders. Open Shareholders

Funds

HolderSharesValueAs of
Vanguard Total Stock Market Index Fund2.18MUS$242MJun 30, 2026
PRIMECAP Odyssey Aggressive Growth Fund1.97MUS$195MJul 31, 2026
SMALLCAP World Fund Inc1.71MUS$190MJun 30, 2026
Vanguard Small-Cap Index Fund1.57MUS$175MJun 30, 2026
iShares Russell 2000 ETF1.42MUS$157MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF1.16MUS$129MJun 30, 2026
Federated Hermes Kaufmann Fund1.03MUS$102MJul 31, 2026
PRIMECAP Odyssey Growth Fund1.01MUS$100MJul 31, 2026
Vanguard Small-Cap Growth Index Fund906KUS$101MJun 30, 2026
T. Rowe Price New Horizons Fund, Inc.780KUS$86.6MJun 30, 2026
Show 50 holders
HolderSharesValueAs of
JPMorgan Mid Cap Growth Fund748KUS$83MJun 30, 2026
Vanguard Extended Market Index Fund716KUS$79.5MJun 30, 2026
Federated Hermes Kaufmann Small Cap Fund610KUS$60.5MJul 31, 2026
Fidelity Small Cap Index Fund603KUS$59.9MJul 31, 2026
Vanguard Explorer Fund560KUS$55.6MJul 31, 2026
Harbor Small Cap Growth Fund512KUS$50.8MJul 31, 2026
iShares Russell 2000 Growth ETF510KUS$56.6MJun 30, 2026
BlackRock Health Sciences Opportunities Portfolio471KUS$41.6MMay 29, 2026
iShares Biotechnology ETF470KUS$52.2MJun 30, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund466KUS$51.7MJun 30, 2026
JPMorgan Growth Advantage Fund456KUS$50.6MJun 30, 2026
Invesco Discovery Fund357KUS$31.5MMay 31, 2026
Fidelity Small Cap Growth Fund348KUS$34.6MJul 31, 2026
Fidelity Extended Market Index Fund311KUS$27.5MMay 31, 2026
Schwab U.S. Small-Cap ETF292KUS$25.8MMay 31, 2026
JPMorgan Small Cap Growth Fund282KUS$31.3MJun 30, 2026
Vanguard Russell 2000 Index Fund272KUS$24MMay 31, 2026
Putnam Small Cap Growth Fund271KUS$30.1MJun 30, 2026
ClearBridge Small Cap Growth Fund245KUS$24.3MJul 31, 2026
T. Rowe Price Health Sciences Fund, Inc.242KUS$26.8MJun 30, 2026
Loomis Sayles Small Cap Growth Fund235KUS$26.1MJun 30, 2026
AB Small Cap Growth Portfolio232KUS$25.8MJun 30, 2026
JNL/JPMorgan MidCap Growth Fund204KUS$22.7MJun 30, 2026
AB Discovery Growth Fund, Inc.179KUS$19.9MJun 30, 2026
Fidelity Small Cap Growth K6 Fund177KUS$17.6MJul 31, 2026
Vanguard Health Care Index Fund170KUS$15MMay 31, 2026
Janus Henderson Global Life Sciences Fund158KUS$17.6MJun 30, 2026
Schwab Small-Cap Index Fund134KUS$13.3MJul 31, 2026
Bridge Builder Tax Managed Small/Mid Cap Fund132KUS$14.6MJun 30, 2026
Voya Small Cap Growth Fund128KUS$11.3MMay 31, 2026
Columbia Acorn Fund125KUS$13.9MJun 30, 2026
Fidelity Total Market Index Fund115KUS$10.1MMay 31, 2026
Artisan Small Cap Fund112KUS$12.4MJun 30, 2026
Fidelity Enhanced Small Cap Core ETF107KUS$11.9MJun 30, 2026
JPMorgan Mid Cap Equity Fund107KUS$11.8MJun 30, 2026
JPMorgan Active Growth ETF102KUS$11.3MJun 30, 2026
Master Small Cap Index Series102KUS$11.3MJun 30, 2026
Select Biotechnology Portfolio99,803US$8.81MMay 31, 2026
Columbia Small Cap Growth Fund98,841US$8.73MMay 31, 2026
Fidelity Series Total Market Index Fund93,212US$8.23MMay 31, 2026

This page holds 50 of 327 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Shulman Joseph
Officer: Chief Technical Officer
Sale45,921USD 119.90US$5.51MNov 18, 2026
Jean Christophe
Director
Sale5,000USD 106.81US$534KNov 17, 2026
Jean Christophe
Director
Sale2,500USD 110.00US$275KNov 17, 2026
Jean Christophe
Director
Sale2,500USD 115.00US$288KNov 17, 2026
Meeker David P
Director, Officer: President and CEO
Sale6,439USD 101.75US$655KSep 14, 2026
Meeker David P
Director, Officer: President and CEO
Sale30,746USD 102.35US$3.15MSep 14, 2026
Meeker David P
Director, Officer: President and CEO
Sale8,698USD 103.43US$900KSep 14, 2026
Meeker David P
Director, Officer: President and CEO
Sale1,817USD 104.55US$190KSep 14, 2026
Meeker David P
Director, Officer: President and CEO
Sale2,300USD 105.19US$242KSep 14, 2026
Smith Hunter C
Officer: Chief Financial Officer
Sale23,072USD 104.59US$2.41MAug 31, 2026
All 26 trades
TradeTradeSharesPriceValueDate
Smith Hunter C
Officer: Chief Financial Officer
Sale11,514USD 105.37US$1.21MAug 31, 2026
Smith Hunter C
Officer: Chief Financial Officer
Sale28,188USD 106.20US$2.99MAug 31, 2026
Garfield Alastair
Officer: Chief Scientific Officer
Sale2,007USD 116.11US$233KAug 13, 2026
Garfield Alastair
Officer: Chief Scientific Officer
Sale1,556USD 117.08US$182KAug 13, 2026
Garfield Alastair
Officer: Chief Scientific Officer
Sale3,400USD 118.28US$402KAug 13, 2026
Garfield Alastair
Officer: Chief Scientific Officer
Sale800USD 119.17US$95,336Aug 13, 2026
Shulman Joseph
Officer: Chief Technical Officer
Sale5,079USD 119.75US$608KAug 13, 2026
Lee Jennifer Kayden
Officer: EVP, Head of North America
Sale75,834USD 117.38US$8.9MAug 13, 2026
Mazabraud Yann
Officer: EVP, Head of International
Sale2,300USD 111.80US$257KAug 12, 2026
Mazabraud Yann
Officer: EVP, Head of International
Sale1,000USD 112.86US$113KAug 12, 2026
Mazabraud Yann
Officer: EVP, Head of International
Sale3,605USD 114.70US$413KAug 12, 2026
Mazabraud Yann
Officer: EVP, Head of International
Sale14,568USD 115.43US$1.68MAug 12, 2026
Mazabraud Yann
Officer: EVP, Head of International
Sale18,208USD 116.49US$2.12MAug 12, 2026
Mazabraud Yann
Officer: EVP, Head of International
Sale17,319USD 117.47US$2.03MAug 12, 2026
Tetrault Lynn A.
Director
Sale37,000USD 100.32US$3.71MJun 22, 2026
German Christopher Paul
Officer: Corporate Controller & CAO
Sale4,643USD 92.21US$428KMay 15, 2026

Big stakes

StakeStakeSharesDateFiling
Ra Capital Management, L.P.9.90%6.67MDec 31, 2025Schedule 13G
Baker Bros. Advisors LP8.90%5.6MMar 31, 2025Schedule 13G
BlackRock, Inc.6.90%4.36MMar 31, 2025Schedule 13G
Primecap Management Co5.21%3.48MDec 31, 2025Schedule 13G
JPMorgan Chase & Co5.10%3.56MSep 30, 2026Schedule 13G
Perceptive Advisors LLC5.10%3.52MMar 31, 2026Schedule 13G
Vanguard Capital Management LLC5.02%3.43MMar 31, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Edward Mathers
Other companies: NeueHealth Inc (Director · Since at least Oct 2, 2025); MBX Biosciences, Inc. (Director · Since at least Sep 12, 2024); Senti Biosciences Holdings, Inc. (Director · Since at least Jun 8, 2022); OnKure Therapeutics, Inc. (Director · Since at least Apr 8, 2021); Trevi Therapeutics, Inc. (Director · Since at least May 7, 2019); Inozyme Pharma Inc (Director · Jul 23, 2020 – Jun 18, 2024 · Past); Akouos Inc (Director · Jun 25, 2020 – Dec 1, 2022 · Past); Mirum Pharmaceuticals, Inc. (Director · Jul 17, 2019 – Jun 2, 2022 · Past); Ra Pharmaceuticals Inc (Director · Jun 28, 2018 – Apr 2, 2020 · Past); Synlogic Inc (Director · Dec 29, 2017 – Jun 22, 2023 · Past)
Director · Since at least Oct 4, 2017
Kimberly Popovits
Other companies: Kardigan, Inc. (Director · Since at least Jun 17, 2026); EXACT Sciences Corporation (Director · Since at least Jan 2, 2025); 10x Genomics, Inc. (Director · Since at least Mar 26, 2020); Kiniksa Pharmaceuticals International, plc (Director · Since at least May 23, 2018); Talis Biomedical Corp (Director · Feb 11, 2021 – Jun 9, 2023 · Past); MyoKardia Inc (Director · Mar 15, 2017 – Nov 17, 2020 · Past); Genomic Health Inc (President and CEO, Director · Nov 3, 2016 – Nov 8, 2019 · Past)
Director · Since at least Apr 1, 2026
David Meeker
Other companies: Kardigan, Inc. (Board of Directors · Since at least Jun 17, 2026); Pharvaris N.V. (Chair of the Board · Since at least Mar 18, 2026); Trevi Therapeutics, Inc. (Chairman · Since at least May 7, 2019); Turmeric Acquisition Corp (Director · Oct 15, 2020 – Oct 15, 2020 · Past); MyoKardia Inc (Director · Apr 17, 2017 – Nov 17, 2020 · Past); Savient Pharmaceuticals Inc (Director · Jan 7, 2013 – Jan 7, 2013 · Past)
Chairman, President, and Chief Executive Officer · Since at least Oct 4, 2017
David McGirr
Other companies: X4 Pharmaceuticals, Inc. (Director · Since at least Nov 15, 2017); Insmed Incorporated (Director · Since at least Oct 30, 2013); Roka Bioscience Inc (Director · Jul 16, 2014 – Jun 28, 2017 · Past); Relypsa Inc (Director · Nov 14, 2013 – Sep 1, 2016 · Past); Cubist Pharmaceuticals Inc (SVP & Chief Financial Officer · Mar 31, 2010 – Feb 15, 2013 · Past)
Director · Since at least Oct 4, 2017
Neil Exter
Other companies: Maze Therapeutics, Inc. (Director · Since at least Jan 30, 2025); Decibel Therapeutics Inc (Director · Feb 11, 2021 – Jun 17, 2022 · Past); Pliant Therapeutics, Inc. (Director · Jun 2, 2020 – Jun 16, 2022 · Past); Revolution Medicines, Inc. (Director · Feb 12, 2020 – Jun 16, 2022 · Past); CytomX Therapeutics, Inc. (Director · Oct 7, 2015 – Jun 20, 2017 · Past)
Director · Oct 4, 2017 – Jun 6, 2018 · Past
Stuart Arbuckle
Other companies: Praxis Precision Medicines, Inc. (Director · Since at least Jan 8, 2026); Alnylam Pharmaceuticals, Inc. (Director · Since at least Jan 5, 2026); Vertex Pharmaceuticals Incorporated (EVP, COO · Since at least May 25, 2016); ImmunoGen Inc (Director · Jan 23, 2018 – Feb 12, 2024 · Past); Dare Bioscience, Inc. (Director · Jun 22, 2016 – Jan 3, 2017 · Past)
Director · Since at least Jul 23, 2019
Jonathan Silverstein
Other companies: Arcutis Biotherapeutics, Inc. (Director · Jan 30, 2020 – Oct 2, 2020 · Past); Adicet Bio, Inc. (Director · Jan 25, 2018 – Jun 3, 2020 · Past); Glaukos Corporation (Director · Dec 13, 2017 – Mar 2, 2018 · Past); Scpharmaceuticals Inc (Director · Nov 16, 2017 – Nov 21, 2017 · Past)
Director · Oct 4, 2017 – Oct 4, 2017 · Past
Jennifer Good
Other companies: Trevi Therapeutics, Inc. (President and Chief Executive Officer · Since at least May 7, 2019); Juniper Pharmaceuticals Inc (Director · Sep 7, 2017 – Aug 14, 2018 · Past); Penwest Pharmaceuticals Co (President & CEO · Apr 28, 2010 – Nov 4, 2010 · Past)
Director · Since at least Jun 19, 2019
Keith Gottesdiener
Other companies: Septerna, Inc. (Director · Since at least Sep 25, 2025); Prime Medicine, Inc. (See Remarks, Director · Oct 19, 2022 – May 8, 2025 · Past); Intercept Pharmaceuticals Inc (Director · Jul 19, 2016 – Nov 8, 2023 · Past)
CEO & President, Director · Oct 4, 2017 – Mar 9, 2020 · Past
Lynn A. Tetrault
Other companies: Alumis Inc. (Director · Since at least May 21, 2025); NeoGenomics, Inc. (Director · Since at least Jun 2, 2021); Acelyrin, Inc. (Director · Dec 18, 2023 – May 21, 2025 · Past)
Director · Since at least Dec 9, 2020
All 24 people
PersonSeat
Camille L. Bedrosian
Other companies: Crinetics Pharmaceuticals, Inc. (Director · Since at least Jun 11, 2025); Amylyx Pharmaceuticals, Inc. (Chief Medical Officer · Since at least Mar 31, 2025)
Director · Since at least Jun 18, 2025
Hunter Smith
Other companies: Spyre Therapeutics, Inc. (Director · Nov 12, 2021 – Jun 22, 2023 · Past); Genesee & Wyoming Inc (Director · Jun 30, 2015 – Dec 30, 2019 · Past)
Chief Financial Officer and Treasurer · Since at least Oct 4, 2017
Fred T Fiedorek
Other companies: Verve Therapeutics Inc (Chief Medical Officer · Sep 18, 2023 – Feb 14, 2024 · Past)
Chief Medical Officer · Oct 4, 2017 – Feb 14, 2018 · Past
Jennifer Chien
Other companies: Krystal Biotech, Inc. (Chief Commercial Officer · Jan 20, 2020 – Jan 31, 2020 · Past)
EVP, Head of North America · Since at least Nov 9, 2020
Alastair GarfieldChief Scientific Officer · Since at least Jul 1, 2025
Alicia FiscusChief Regulatory Officer · Since at least Nov 5, 2026
Christophe R. JeanDirector · Since at least Jun 18, 2025
Christopher Paul GermanCorporate Controller & CAO · Since at least Aug 11, 2023
Elisabeth Crönert-BendellSenior Vice President, Head of Strategy · Since at least Nov 5, 2026
Jennifer LeeExecutive Vice President, Head of North America · Since at least Aug 14, 2026
Jim FlahertySenior Vice President and General Counsel · Since at least Nov 5, 2026
Joe ShulmanChief Technical Officer · Since at least Jul 9, 2025
Manher JoshiChief Medical Officer · Since at least Aug 17, 2026
Yann MazabraudEVP, Head of International · Since at least Oct 5, 2020

Open People

Log in to ask 6ix AI your own questions about Rhythm Pharmaceuticals, Inc.